Skip to main content

Precision BioSciences, Inc.

corporate_fare Company Profile

Precision BioSciences, Inc.

DTIL·NASDAQ·Life Sciences·CIK 0001357874

We are a clinical stage gene editing company that uses our proprietary ARCUS platform to develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is distinct from other technologies due to its cutting mechanism, smaller size, and simpler structure. This platform is utilized to create in vivo gene editing therapies for complex gene edits, including gene insertion (adding DNA to a gene to enable expression or add function), elimination (removing a genome, such as viral DNA), and excision (removing a large part of a defective gene by delivering two ARCUS nucleases within a single adeno-associated virus ("AAV")). Genome editing is a biotechnology process that removes, inserts, or repairs a segment of DNA at a specific location within a cell's genome. While early applications focused on genetic research, advancements in genome editing technologies are now enabling their use in treating or preventing diseases by editing DNA. This process is achieved by delivering a DNA cutting enzyme, known as an endonuclease, to a targeted segment of genetic code.

Precision BioSciences, Inc. (NASDAQ:DTIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for DTIL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Precision BioSciences Details PBGENE-DMD Phase 1/2 Trial for Duchenne Muscular Dystrophy
  • Precision BioSciences Reports Full-Year Loss, Secures Cash Runway to 2028 Amidst Major Dilutive Offering & Key Clinical Progress
  • Precision BioSciences Reports Strong Q4 Profitability, Extends Cash Runway to 2028, and Advances Gene Editing Pipeline
  • Precision BioSciences Q4 Revenue Soars Past Estimates by Over 3x
  • Precision BioSciences Secures Key U.S. Patent Allowances for PBGENE-HBV Program

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$34.26M
Net Income
-$45.72M
Diluted EPS
-$3.56
Op. Cash Flow
-$65.84M
Free Cash Flow
-$65.93M
Operating Income
-$52.15M
Cash & Equivalents
$110.82M
Debt / Equity
0.00×
Net Margin
-133.4%
Shares Outstanding
24.09M sh
Source: 10-K · filed 2026-03-12 · accession 0001628280-26-017019
$7.4
52-week range · as of 2026-11-05 $3.53 – $9.62
Market cap
$206.72M
Volume
429.8K (1.1× avg)
3-mo avg 393.6K
Live data · 2026-11-22 03:39 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DTIL - Filings & News (Page 2)

DTIL
Mar 17, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.34
Real-time Price: $7.40 info
Change: +$1.06 (+17%) info
Market Cap: $206.724M info
DTIL
Mar 12, 2026, 7:31 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $7.40 info
Change: +$1.79 (+32%) info
Market Cap: $206.724M info
DTIL
Mar 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.49
Real-time Price: $7.40 info
Change: +$1.91 (+35%) info
Market Cap: $206.724M info
DTIL
Mar 12, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.40
Real-time Price: $7.40 info
Change: +$2.00 (+37%) info
Market Cap: $206.724M info
DTIL
Mar 11, 2026, 7:02 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.35
Real-time Price: $7.40 info
Change: +$2.05 (+38%) info
Market Cap: $206.724M info
DTIL
Feb 11, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $7.40 info
Change: +$3.41 (+85%) info
Market Cap: $206.724M info
DTIL
Jan 13, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.11
Real-time Price: $7.40 info
Change: +$3.29 (+80%) info
Market Cap: $206.724M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets